Paragon 28's stock has seen a significant recovery from its low point of $4.89 in the third quarter of 2024, with InvestingPro data showing an impressive six-month return of 38.4%.

The Ademi Firm is investigating Paragon 28 (NYSE: FNA) for possible breaches of fiduciary duty and other violations of law in its transaction with Zimmer Biomet. Click here to learn how to join our ...

M VM Partners, LLC, a significant stakeholder in Paragon 28, Inc. (NASDAQ:FNA), disclosed the sale of 111,465 shares of common stock, valued at approximately $1.32 million. The transactions ...

ENGLEWOOD, Colo., March 11, 2025--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) ("Paragon 28" or "Company"), a leading medical device company exclusively focused on the foot and ankle orthopedic ...

ENGLEWOOD, Colo., March 07, 2025--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, is pleased to ...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Paragon 28, Inc. (NYSE: FNA) to Zimmer Biomet Holdings, Inc. for $13.00 per share in ...

Paragon 28 (NYSE:FNA – Get Free Report) is anticipated to issue its quarterly earnings data before the market opens on Thursday, March 6th. Analysts expect the company to announce earnings of ($ ...

Paragon 2 (FNA) announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976in connection with the previously announced acquisition of Paragon 28 ...

Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or “Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced the expiration of ...

ENGLEWOOD, Colo., March 11, 2025--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) ("Paragon 28" or "Company"), a leading medical device company exclusively focused on the foot and ankle orthopedic ...